stephen schuster

Dr. Stephen Schuster, M.D.

Scientific Advisor

Stephen J. Schuster, MD, is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the director of the lymphoma program and director of Lymphoma Translational Research at the Abramson Cancer Center. After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College.

Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous costimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells) Dr. Schuster has received numerous awards for outstanding teaching and research. He has over 200 publications. Schuster, director of the Lymphoma Program at the Abramson Cancer Center, University of Pennsylvania, was the principal investigator for the trial that led to the approval of tisagenlecleucel, or tisa-cel (Kymriah). He has also led trials involving bisp

stephen schuster

Dr. Stephen Schuster, M.D.

Scientific Advisor

Stephen J. Schuster, MD, is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the director of the lymphoma program and director of Lymphoma Translational Research at the Abramson Cancer Center. After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College.

Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous costimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells) Dr. Schuster has received numerous awards for outstanding teaching and research. He has over 200 publications. Schuster, director of the Lymphoma Program at the Abramson Cancer Center, University of Pennsylvania, was the principal investigator for the trial that led to the approval of tisagenlecleucel, or tisa-cel (Kymriah). He has also led trials involving bisp